Abstract

Cannabis is increasingly legalized in more areas of the USA and marketed under the misnomer “medical cannabis.” Yet, there are no official dosing guidelines or approved medical uses for plant cannabis by the Food and Drug Administration. Due to significant federal barriers, research on efficacy, safety, and adverse effects of cannabis is limited. Patients are interested in cannabis as potential treatment of medical issues and/or symptoms and clinicians should include a discussion of the risks of cannabis consumption. However, many risks are not yet known, and clinicians might be unaware of the emerging literature. This perspective summarizes the potential harms of cannabis, including the risk of cannabis use disorder, while providing a framework grounded in principles of medical ethics to educate patients on cannabis.

Original languageEnglish
JournalJournal of General Internal Medicine
DOIs
StateAccepted/In press - 2025

Bibliographical note

Publisher Copyright:
© The Author(s), under exclusive licence to Society of General Internal Medicine 2025.

Funding

Work on this was supported by the University of Kentucky (UK) Bell Addiction Medicine Scholar Program.

FundersFunder number
University of Kentucky

    ASJC Scopus subject areas

    • Internal Medicine

    Fingerprint

    Dive into the research topics of '“Medical Cannabis”: Advising Patients While Navigating Medical Ethics and Limited Evidence'. Together they form a unique fingerprint.

    Cite this